Abstract
Various High-Dose Rate (HDR) monotherapy dose regimens are currently being used to treat low and intermediate risk prostate cancer patients. There is no consensus on the regimen with the best long-term outcomes. The objective of this study is to assess the Southeastern Regional Medical Center (SERMC) institutional experience with HDR monotherapy for low and intermediate prostate cancers. Biochemical progression free survival and toxicity was evaluated for patients receiving two fractions of 13.5 Gy with three weeks between each fraction.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
